AMENDMENTS TO THE CLAIMS

Claims 1-19 (Cancelled)

20. (Currently Amended) A liquid preparation consisting of: (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the ~~formula [I]:~~



~~[I]~~

~~wherein R^1 is a substituted or unsubstituted lower alkyl group, X^1 is a group of the formula: $-NHR^2$ (wherein R^2 is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,~~

~~(b) a buffer and~~

~~(c) water,~~

~~which is adjusted to pH 5 - 8 with said buffer.~~

formula:



or a pharmaceutically acceptable salt thereof and a carboxymethylated dextran or pulluran via glycyl-glycyl-glycine, (b) a buffer and (c) water, which is adjusted to pH 5 - 8 with said buffer.

21. (Currently Amended) A liquid preparation consisting of: (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the ~~formula [I]:~~



~~wherein R^1 is a substituted or unsubstituted lower alkyl group, X^1 is a group of the formula: $-NHR^2$ (wherein R^2 is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,~~

formula:



or a pharmaceutically acceptable salt thereof and a carboxymethylated dextran or pulluran via glycyl-glycyl-glycine, (b) one or more stabilizers selected from an alkali metal carbonate and an alkali metal hydrogencarbonate, (c) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and (d) water, which is adjusted to pH 5 - 8 with said buffer.

22. (Currently Amended) A liquid preparation consisting of: (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the ~~formula [I]:~~



~~wherein R^1 is a substituted or unsubstituted lower alkyl group, X^1 is a group of the formula: $-NHR^2$ (wherein R^2 is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,~~

formula:



or a pharmaceutically acceptable salt thereof and a carboxymethylated dextran or pulluran via glycyl-glycyl-glycine, (b) one or more salts selected from the group consisting of an alkali metal chloride, an alkali earth metal chloride and an alkali metal sulphate, (c) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and (d) water, which is adjusted to pH 5 - 8 with said buffer.

23. (Currently Amended) A liquid preparation consisting of: (a) 1 w/v% to 20 w/v% of a camptothecin derivative which is prepared by binding a compound of the ~~formula [I]:~~



~~wherein R^1 is a substituted or unsubstituted lower alkyl group, X^1 is a group of the formula: NHR^2 (wherein R^2 is a hydrogen atom or a lower alkyl group) or a hydroxyl group and Alk is a straight or branched chain alkylene group optionally interrupted by an oxygen atom, and a polysaccharide having carboxyl groups via an amino acid or a peptide, or a pharmaceutically acceptable salt thereof,~~

formula:



or a pharmaceutically acceptable salt thereof and a carboxymethylated dextran or pulluran via glycyl-glycyl-glycine, (b) one or more salts selected from the group consisting of an alkali metal chloride, an alkali earth metal chloride and an alkali metal sulphate, (c) one or more stabilizers selected from an alkali metal carbonate and an alkali metal hydrogencarbonate, (d) a buffer comprising one or more compounds selected from the group consisting of citric acid, an alkali metal citrate, acetic acid, an alkali metal acetate and an alkali metal dihydrogenphosphate and (e) water, which is adjusted to pH 5 - 8 with said buffer.

Claim 24 (Cancelled)

25. (Currently Amended) The liquid preparation according to ~~claim 24~~ claim 20, 21, 22 or 23 wherein ionic strength of the buffer is 0.2 or less than 0.2.

26. (Previously Presented) The liquid preparation according to claim 25 wherein the pH is adjusted to 5 to 7.5.

27. (Previously Presented) The liquid preparation according to claim 25 wherein the pH is adjusted to 5 to 7.

28. (Previously Presented) The liquid preparation according to claim 25 wherein the pH is adjusted to 6 to 7.

29. (Currently Amended) A lyophilized drug composition which is prepared by lyophilizing the liquid preparation claimed in ~~claim 24~~ claim 20, 21, 22 or 23.

30. (Previously Presented) The liquid preparation according to claim 23, wherein the salt is sodium chloride.

Claims 31-34 (Cancelled)